Additional studies are required to identify potential NAFLD-activated molecular pathways involved in the down-regulation of FGF21-FGF19/Klotho network and its potential role in NAFLD-related progression, i.e. NASH, fibrosis and HCC. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.